Inactive Instrument

Alzheon, Inc.

Equities

ALZH

US00168L1017

Biotechnology & Medical Research

Alzheon, Inc. announced that it expects to receive $50.000004 million in funding

September 13, 2020

Alzheon, Inc. announced that it will issue 1,388,889 series D preferred shares at issue price of $36 per share for the gross proceeds $50,000,004 on September 14, 2020. The shares will be convertible in common shares at a fixed price of $36 per share. The round will be raised at post money valuation of $697,842,252.

The company will issue securities pursuant to exemption provided under Regulation D. The company intends to continue the transaction for more than one year.

Latest news about Alzheon, Inc.

Alzheon, Inc. announced a financing transaction	Feb. 26	CI
Alzheon Promotes Glenn E. Pauly to Chief Commercial Officer	Dec. 05	CI
Alzheon, Inc. to Present Biomarker, Brain Preservation, and Clinical Results from Pivotal Program of Oral ALZ-801/Valiltramiprosate at 16th Annual Clinical Trials in Alzheimer's Disease Conference	23-10-17	CI
Alzheon To Present Pivotal Program of Oral ALZ-801/Valiltramiprosate at Singularity Conference, Goldman Sachs Alzheimer?s Disease Day, and BIO Investor Forum	23-09-26	CI
Alzheon Reports Biomarker, Brain Preservation and Clinical Benefits Following 24 Months of Treatment in Phase 2 Trial of Oral ALZ-801 in Patients with Early Alzheimer's Disease	23-09-13	CI
Alzheon to Present Baseline Imaging Characteristics from Ongoing APOLLOE4 Phase 3 Trial of Oral Tablet	23-07-11	CI
Alzheon, Inc. to Present Baseline Imaging Characteristics from Ongoing APOLLOE4 Phase 3 Trial of Oral Tablet ALZ-801 (Valiltramiprosate) and Results of Phase 2 Biomarker Study At American Academy of Neurology Conference in Boston	23-04-18	CI
Alzheon, IncAnnounces Early Completion of Enrollment of APOLLOE4 Phase 3 Clinical Trial Evaluating Oral ALZ-801 (Valiltramiprosate) in APOE4/4 Homozygotes with Early Alzheimer’s Disease	22-12-06	CI
Alzheon, Inc. announced that it expects to receive $50.004201 million in funding	22-11-29	CI
Alzheon, Inc. Reports Brain Preservation and Clinical Effects Following 12 Months of Treatment in Phase 2 Trial of Oral Alz-801 (Valiltramiprosate) in Patients with Early Alzheimer’S Disease	22-09-20	CI
Alzheon, Inc Appoints Glenn Pauly as Head of Commercial	22-09-20	CI
Alzheon, Inc. to Present Industry-Leading Phase 2 Biomarker and Clinical Data with ALZ -801 (Valiltramiprosate) Oral Tablet At 2022 Alzheimer’S Association International Conference	22-07-26	CI
Alzheon, Inc. announced that it has received $50.000004 million in funding	22-04-13	CI
Alzheon to Present ALZ-801 (Valiltramiprosate) Phase 3 Program Update and Industry-Leading Disease Modifying Effects from Phase 2 Trial in Patients with Early Alzheimer’s Disease At AD/PD and NDDS Scientific Conferences	22-03-08	CI
Alzheon Reports Disease Modifying Effects from Phase 2 Biomarker Trial of Oral Tablet ALZ-801 (Valiltramiprosate) in Patients with Early Alzheimer’s Disease	22-02-08	CI
Alzheon to Present New Data from Ongoing Phase 2 Biomarker Trial of ALZ-801 Oral Tablet at Clinical Trials in Alzheimer?s Disease Conference	21-11-01	CI
Alzheon Appoints Adem Albayrak as Head of Operations	21-09-13	CI
Alzheon, Inc. Completes Patient Enrollment in Phase 2 Biomarker Trial of ALZ-801 Oral Tablet in APOE4 Carriers with Alzheimer’s Disease	21-06-23	CI
Alzheon, Inc. Announces Publication of Peer-Reviewed Scientific Demonstrates Central Role of Neurotoxic Soluble Amyloid Oligomers in Driving Alzheimer’s Pathogenesis	21-06-23	CI
Alzheon Announces First Patient Dosed in APOLLOE4 Phase 3 Trial of Oral ALZ-801 in Patients with Early Alzheimer’s Disease	21-06-04	CI
Alzheon, Inc. Partners with Institute of Organic Chemistry and Biochemistry to Develop First Alzheimer’s Diagnostic Assay for Measuring Neurotoxic Beta Amyloid Oligomers in Human Brain	21-05-04	CI
Alzheon CEO Presents Overview of Oral Anti-Amyloid Alz-801 Phase 3 Program at 9Th Neurodegenerative Drug Development Summit	21-02-24	CI
Alzheon, Inc. Announces Dosing of First Patient in ALZ-801 Phase 2 Biomarker Study in APOE4 Carriers with Early Alzheimer’S Disease	20-10-27	CI
Alzheon, Inc. announced that it expects to receive $50.000004 million in funding	20-09-13	CI
Alzheon, Inc. Receives $47 Million Grant from U.S. National Institute on Aging for Phase 3 Clinical Study of ALZ-801, an Oral Treatment for Alzheimer’s Disease	20-08-20	CI

Chart Alzheon, Inc.

Duration

Period

More charts

Company Profile

Alzheon Inc is a United States-based clinical-stage biopharmaceutical company. The company is developing medicines for patients suffering from alzheimer's disease and other neurological and psychiatric disorders. The Company is focused on brain health, memory and aging and develops treatments for alzheimer's disease and other neurodegenerative disorders.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IQVIA HOLDINGS INC.	+1.77%	42.86B
LONZA GROUP AG	+46.79%	41.36B
MODERNA, INC.	+12.24%	42.74B
CELLTRION, INC.	-8.83%	27.68B
ICON PUBLIC LIMITED COMPANY	+7.44%	25.15B
ALNYLAM PHARMACEUTICALS, INC.	-23.01%	18.63B
MEDPACE HOLDINGS, INC.	+30.56%	12.37B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.82%	11.92B
UNITED THERAPEUTICS CORPORATION	+8.35%	11.21B

Other Biotechnology & Medical Research